CD274 and neoplasm: Combining 225Ac-DOTA-4AH29 with PD-L1 immune checkpoint blockade further enhanced therapeutic efficacy, resulting in greater tumor growth inhibition and prolonged survival compared to 225Ac-DOTA-4AH29 monotherapy or control treatments.